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Abstract
Tumours arising from mesenchymal tissue components such as vascular, fibrous and adipose tissue can manifest in the
liver. Although histopathology is often necessary for definitive diagnosis, many of these lesions exhibit characteristic
imaging features. The radiologist plays an important role in suggesting the diagnosis, which can direct appropriate
immunohistochemical staining at histology. The aim of this review is to present clinical and imaging findings of a
spectrum of mesenchymal liver tumours such as haemangioma, epithelioid haemangioendothelioma, lipoma, PEComa,
angiosarcoma, inflammatory myofibroblastic tumour, solitary fibrous tumour, leiomyoma, leiomyosarcoma, Kaposi
sarcoma, mesenchymal hamartoma, undifferentiated embryonal sarcoma, rhabdomyosarcoma and hepatic metastases.
Knowledge of the characteristic features of these tumours will aid in guiding the radiologic diagnosis and appropriate
patient management.

Introduction
Mesenchymal tumours are neoplasms that arise from vascular,
fibrous, adipose, and other mesenchymal tissue components.
Aside from haemangiomas, mesenchymal tumours are relatively uncommon in the liver. When they do arise within
the liver, their appearance may mimic common malignant
neoplasms. Hence, differentiation of these rare tumours
from more common entities is relevant to clinical practice.
Although histopathology is often necessary for definitive
diagnosis, many of these lesions exhibit characteristic imaging
features. The radiologist may be the first to suggest the diagnosis, which can direct appropriate immunohistochemical
staining at histology. Recognition of these tumours can direct
management with percutaneous tissue sampling rather than
more invasive intervention. In some cases, identification
of typical imaging findings may even prevent unnecessary
biopsy. In this article, we review a spectrum of common and
uncommon mesenchymal liver tumours and their imaging
findings.
Haemangioma
Haemangiomas are the most common mesenchymal
liver tumour, with a reported incidence of 1–6%.1,2

Histopathologically, haemangiomas are classified into three
main subtypes: cavernous, capillary and sclerosing. Differentiating haemangiomas from other less common tumours
is an issue often encountered in liver imaging, particularly
with atypical forms of haemangiomas.
Cavernous haemangioma
The most common subtype, cavernous haemangiomas
demonstrate a characteristic appearance on imaging. On
ultrasound, cavernous haemangiomas typically appear
as well-defined homogenous hyperechoic lesions with
posterior acoustic enhancement. Dynamic CT/MR shows
peripheral globular/nodular enhancement in arterial phase,
with an attenuation of the enhancing portions similar to
the aorta.3 Progressive centripetal enhancement in the
portal venous phase, and retention of contrast/“fill-in” on
the delayed phase, are classic and also tend to follow blood
pool.4 On T2 weighted MR images, they demonstrate high
signal intensity, which slightly attenuates on longer TE
T2 weighted sequences, due to inherent vascular lakes and
channels.5 Overall, MRI has an accuracy exceeding 97%.5,6
A cavernous haemangioma greater than 5 cm is characterized as a giant haemangioma. This typically has a
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heterogeneous appearance due to central thrombus, myxoid
tissue or fibrosis.7 On dynamic contrast CT/MRI, the typical early
globular peripheral enhancement is present but complete filling
is not seen. Its distinctive MRI appearance of high signal intensity
on T2 weighted images and discontinuous peripheral enhancement with enlargement and coalescence of the enhancing foci
on serial post-contrast images aids in its diagnosis.7 MR images
may show a cleft-like area and sometimes internal septa, which
demonstrate T1-hypointensity and T2-hyperintensity.7

Figure 2. Flash-filling/capillary haemangioma: axial contrast-enhanced T1 weighted images of a small lesion (arrow).
Delayed phase image (a) shows persistent enhancement of
the lesion that matches blood pool. In arterial phase (not
shown in the figures), the lesion exhibited a rapid homogenous enhancement. Axial T2 weighted image (b) shows
increased signal intensity of the lesion typical of a flash filling
haemangioma.

Haemorrhage is a rare complication of cavernous haemangiomas, which may occur spontaneously or after anticoagulation
therapy. Symptoms include acute epigastric pain and vomiting.
The diagnosis is made when the typical enhancement pattern of
haemangioma is combined with features suggestive of intratumoral haemorrhage, such as high attenuation on non-contrast
CT and high signal on T1 weighted images (Figure 1).
Capillary haemangioma
These constitute about 16% of all haemangiomas, and are typically seen in haemangiomas less than 1–2 cm in diameter—the
“flash-filling” haemangioma.8 Dynamic CT/MRI shows rapid
enhancement on the arterial phase (roughly equivalent to the
aorta) with contrast retention on the venous and delayed phases
(Figure 2). This feature allows them to be differentiated from
hypervascular tumours (i.e. HCC, hypervascular metastases)
which typically demonstrate contrast wash-out on the delayed
phase.9
Sclerosing haemangioma
Haemangiomas that exhibit degeneration and fibrous replacement are called sclerosed, thrombosed or hyalinized. Due to
high fibrous content they lack the typical imaging features of a
haemangioma, such as early peripheral enhancement, filling
in on dynamic contrast CT/MRI and high signal intensity on
T2 weighted images. Therefore, the prospective diagnosis of
sclerosing haemangioma can be difficult. However, a combination of findings such as transient hepatic attenuation difference
Figure 1. Haemorrhagic haemangioma: axial T2 weighted
image demonstrates a large well-circumscribed haemangioma within the right hepatic lobe with perilesional fluid compatible with subacute blood (arrows).

in the arterial phase, nodular regions of enhancement which
are hyperintense on T2 weighted images, decrease in size over
time, capsular retraction and the presence of additional typical
haemangiomas may suggest the possibility of a sclerosing
haemangioma10 (Figure 3).
Haemangiomatosis
Haemangiomatosis is a rare condition characterized by diffuse
replacement of the liver by haemangiomatous lesions. Haemangiomatosis differs from multiple or giant haemangiomas in that the
boundary of the lesions is poorly defined. Complications include
spontaneous rupture, thrombocytopenia and consumptive coagulopathy (Kasabach–Merritt syndrome).11 On ultrasound, this
appears as a diffuse heterogeneous hyperechoic infiltrative mass
with hypoechoic nodules.11 On dynamic imaging, each lesion
exhibits peripheral enhancement on the arterial phase with
contrast retention on the delayed phase, which suggests its diagnosis (Figure 4). Differential diagnosis includes other vascular
tumours such as epithelioid haemangioendothelioma (EHE) and
angiosarcoma. Histology is generally required for confirmation.12

Figure 3. Sclerosing haemangioma, confirmed by histology:
axial post-contrast T1 weighted MR image in arterial (a) and
delayed (b) phases, demonstrate a well-circumscribed lesion
at the periphery of the right hepatic lobe (arrow) with rim
enhancement on arterial phase and progressive incomplete
filling on delayed phase with capsular retraction.
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Figure 4. Haemangiomatosis. Coronal T2W HASTE demonstrates multiple haemangiomas in a patient with a known
diagnosis of blue rubber bleb nevus syndrome.

Epithelioid haemangioendothelioma
Hepatic EHE is a rare tumour of vascular origin, akin to haemangioma and angiosarcoma. It is a low-grade malignant tumour
that has an intermediate clinical outcome in between that of a
benign hepatic cavernous haemangioma and malignant angiosarcoma. The vascular nature of the tumour is confirmed by
positive staining for factor III related antigen and other endothelial cell markers (CD31, CD34).
Its peak incidence is between 30 and 50 years of age, and more
commonly affects females.13,14 Extrahepatic involvement at the
time of diagnosis may be detected in up to 36% of patients, with
metastatic spread to lungs, lymph nodes and peritoneum being
the most common sites.15 Recognition of EHE is important
because it may be treated with surgical resection or transplantation even when metastatic disease is present.16
EHE usually manifests as multifocal tumours involving both
lobes of the liver; only 13% are unifocal.15 Tumours are composed
of multiple solid nodules in a predominantly peripheral distribution, which coalesce as they enlarge, and result in capsular
retraction. Tumour nodules have a hyperemic rim on the arterial
phase which retains contrast on the venous phase.13
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Figure 5. Epithelioid haemangioendothelioma: contrast-enhanced CT in the arterial phase, showing multiple coalescent
hypodense lesions with peripheral enhancement, more at the
periphery of the right lobe; these were pathologically proven
to represent EHE. EHE, epithelioid haemangioendothelioma.

of multiple peripheral subcapsular lesions that demonstrate
increased vascularity, and result in hypertrophy of the uninvolved liver.
Lipoma
Lipomas are rarely seen in the liver. Histologically, they consist of
mature adipose tissue. On ultrasound, lipomas are well-circumscribed and homogeneously hyperechoic. They measure fat attenuation on CT with no enhancement on post-contrast imaging.
On MRI, macroscopic adipose tissuedemonstratesloss of signal
on fat-saturated pulse sequences compared with non-fat-saturated pulse sequences. Microscopic adipose tissue demonstrates
loss of signal on out-of-phase T1 weighted images compared to
in-phase images (Figure 6).
Perivascular epithelioid cell neoplasm (PEComa)
Perivascular epithelioid cell neoplasms (PEComa) are rare
mesenchymal tumours composed of histologically and
Figure 6. Hepatic lipoma-gray-scale ultrasound demonstrates
a well-circumscribed echogenic lesion with distal acoustic
shadowing, consistent with lipoma.

The mases are hypoechoic or heterogeneous on ultrasound. On
CT, EHE presents as multiple peripherally located hypodense
rim-enhancing tumours, resulting in capsular retraction in up to
25% of patients.13 They can merge into larger confluent masses
(Figure 5). A target pattern may be seen on contrast-enhanced
CT or MR, characterized by a hypodense central zone, peripheral enhancement and a hypodense rim.13,17–19 Imaging features
may overlap with cholangiocarcinoma or multiple metastases.
Pasquale et al reported a distinguishing feature in a series of 11
cases, in that none of them showed the globular enhancement
pattern typical of haemangioma. EHE may also appear as a solitary subcapsular mass with minimal or rim-like enhancement
at early phase and progressive centripetal fill-in enhancement
during dynamic phase imaging, as seen in some haemangiomas.20 EHE should be favoured over metastatic disease in cases
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immunohistochemically distinctive “perivascular epithelioid cells”, which are unusual cells with dual melanocytic and
myxoid differentiation, typically in a perivascular distribution.21 Although the majority are benign, they can show malignant features with local recurrence and distant metastases. It is
important for radiologists to recognize the imaging findings of
PEComas because treatment with mTOR inhibitors has shown
promising results in malignant PEComas.22
The PEComa group of tumours includes classic angiomyolipoma
(AML), epithelioid AML, clear-cell ‘‘sugar’’ tumours, lymphangioleiomyomatosis, clear-cell myomelanocytic tumour of the falciform ligament/ligamentum teres, and abdominopelvic sarcoma
of PECs. AML is relatively specific to the tuberous sclerosis
complex (TSC), presenting in 80% of patients with tuberous sclerosis and in less than 0.1% of the general population.23 Hepatic
AML is seen in about 30% tuberous sclerosis patients older than
9 years,23 and nearly always seen concurrently with renal AML
in TSC. Tumours comprised solely of PECs are distinguished
from AML by names such as PEComa-NOS or simply PEComa.
Malignant hepatic AML with metastases have been reported, but
these tumours are usually large (greater than 15 cm).24 Additional features associated with malignant AMLs are coagulative
necrosis, rapid growth, metastases, and loss of CD117 expression.
Imaging features of hepatic PEComas vary due to their different
degree of adipose tissue, vessels and smooth muscle. On ultrasound, PEComas are often hyperechoic similar to a haemangioma, but with blood flow within or at the periphery of the
lesion. Lesions with increased smooth muscle components appear
hypoechoic, whereas those with increased vascular components
appear hyperechoic. CT and MRI usually demonstrate both
the fat component and vessels25 (Figure 7). In the presence of
decreased fat content, distinguishing this tumour from other
hypervascular tumours such as HCC may be difficult on CT
and MRI since fatty metamorphosis can occur in HCC.26 AMLs
show a more prolonged enhancement in the portal phase, and
on arterial phase about two-thirds demonstrate curved centralized vessels (whereas in HCC these vessels are more peripheral
in location).25 On MRI, these central vessels are depicted as flow
voids, and vessels coursing within the fat strongly suggest AML27
(Figure 7). When present, ancillary features such as an early
draining vein connecting with tumour vessels or the absence of a
capsule may be useful in differentiating lipid-poor hepatic AML/
PEComas from hepatocellular carcinomas in a non-cirrhotic
liver28 (Figure 8).
Figure 7. Angiomyolipoma: axial non-contrast (a) and contrast-enhanced CT (b) demonstrate a large mass involving the
left hepatic lobe with intralesional fat (arrow in a) and heterogeneous enhancement with prominent vessels (arrow in b).
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Figure 8. Malignant AML (PEComa): axial contrast-enhanced
CT (a) demonstrates a well-circumscribed 2.6 cm mass with
fat attenuation (arrow), initially reported as probably angiomyolipoma. Axial contrast-enhanced CT after 3 years (b)
demonstrates stable size and appearance of the fatty mass.
One year later, axial contrast-enhanced CT in the arterial (c)
and delayed phase (d) demonstrated significant increase in
size with the formation of a hypervascular mass with washout
mimicking HCC, this was pathologically proven as a malignant
AML (PEComa). AML,angiomyolipoma; HCC, hypervascular
metastases; PEComa, perivascular epithelioid cell neoplasm.

Angiosarcoma
Primary hepatic angiosarcoma is a rare but aggressive malignant
vascular neoplasm. Most patients die within a year after diagnosis.29 Prior exposure to thorotrast, arsenic and vinyl chloride
have been implicated as causative factors. It is noted that up to
40% patients have underlying hepatic fibrosis and cirrhosis at
diagnosis.29 There are four reported cases of hepatic angiosarcoma arising from benign lesions such as haemangioendothelioma and haemangioma.30,31 Multifocal involvement is typical,
with at least 10 simultaneous lesions in the majority of patients.29
Abnormal, pleomorphic, malignant endothelial cells are the hallmark of angiosarcoma, which can be rounded, polygonal or fusiform in shape.32 Angiosarcoma typically expresses endothelial
markers and vascular endothelial growth factor. Immunohistochemistry is therefore important in confirming the diagnosis.32
On CT wide variety of appearances may be seen in the late arterial phase, such as heterogeneous, multinodular, rim-like or a
branching pattern of enhancement. The enhancing regions show
progressive enhancement on the portal and delayed phases.
Angiosarcoma classically does not exhibit washout, which is
an important distinguishing feature from multifocal HCC.29
Individual nodules are typically circumscribed and enhancing
(Figure 9). Diffuse “flash-fill” and “reverse haemangioma”
centrifugal enhancement patterns have also been reported.29
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Figure 9. Angiosarcoma: axial contrast-enhanced CT in arterial
(a) and venous (b) show multiple enhancing lesions compatible with angiosarcoma. The largest one exhibits enhancement
pattern somewhat similar to haemangioma with delayed progressive enhancement—but with reversed centripetal pattern.

These multifocal tumours often contain haemorrhage resulting
in heterogeneous appearance on MRI, with areas appearing
hyperintense on T1WI and hypointense on T2WI. Extrahepatic
metastases occur most commonly to the spleen, followed by
peritoneum, pericardium, and lungs.29
Inflammatory myofibroblastic tumour
Inflammatory myofibroblastic tumour (IMT) is known by a
variety of synonyms, such as inflammatory pseudotumour and
plasma cell granuloma.33 It should be considered in the differential diagnosis of a solid liver lesion in the setting of systemic
symptoms (fever, fatigue, pain and weight loss), elevated inflammatory markers [leukocytosis, elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)] and normal
hepatic tumour markers (such as AFP, CA19-9).
Histologically, it consists of spindle cells, myofibroblasts, inflammatory cells and fibrous stroma. Although the exact cause is
unknown, suggested causes include infection (i.e. EBV), vascular
or an autoimmune process.34
The imaging features of IMT vary and are non-specific
depending on the amount of fibrosis and cellular infiltration. It
is solitary in more than 80% of the cases.35 On ultrasound, it can
be hypoechoic or hyperechoic with well-defined or infiltrative
borders and often has increased vascularity on Doppler interrogation. Contrast-enhanced imaging shows various patterns of
enhancement, including heterogeneous, homogeneous, septal
enhancement, peripheral enhancement with delayed central
filling, and lack of enhancement or central necrosis35 (Figure 10).
On MRI, it is usually T1 hypointense and T2 hyperintense with
heterogeneous enhancement.36 Since imaging findings are
non-specific and malignancy is still a consideration, needle
biopsy or resection is usually necessary. There are reported cases
of shrinkage or disappearance of IMT with anti-inflammatory
therapy.37

BJR

Figure 10. Inflammatory myofibroblastic tumour: coronal reformatted image of contrast-enhanced CT images
in a 48-year-old patient with history of Epstein-Barr virus
demonstrates multiple bilobar masses with predominantly
peripheral enhancement in venous phase (arrows). Delayed
phase image (not shown) shows central enhancement of the
masses (arrows). Axial Fluorodeoxyglucose (FDG) PET scan
(b) shows increased FDG uptake of the masses (arrows).

majority were benign and 16 cases demonstrated local recurrence
or metastases.38 Less than 5% of cases can have Doege-Potter
syndrome which is defined as non-islet cell tumour hypoglycemia secondary to SFT, due to secretion of a prohormone form
of insulin-like growth factor II.39 At histopathology, SFT is typically composed of juxtaposed hyper- and hypocellular spindle
cell proliferation, dense collagenous stroma and numerous thinwalled blood vessels with a staghorn configuration, a histologic
hallmark of SFT.40 SFT can be of the cellular or fibrous variant
per the predominant histopathology and the imaging appearance varies accordingly.
At imaging, it is typically a solitary large heterogeneous mass
marked enhancement of the periphery, mimicking other
tumours such as sclerosing haemangioma, sclerosing and fibrolamellar variants of hepatocellular carcinoma (Figure 11). The
fibrous component may show progressive enhancement similar
Figure 11. Solitary fibrous tumour, pathologically proven: axial
contrast-enhanced CT images show a large well defined
hypodense lesion in the right lobe of the liver on precontrast
CT (not shown) with marked peripheral enhancement.

Solitary fibrous tumour
Solitary fibrous tumour (SFT) is a rare tumour composed of
spindle cells and interspersed collagen. It rarely manifests in
the liver; fewer than 100 cases have been reported, of which the
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to cholangiocarcinoma. It exhibits areas of low signal intensity
on T2 weighted images, corresponding to the fibrous component,
which helps differentiate it from the other focal hepatic lesions,
including cholangiocarcinoma, which is classically iso- or hyperintense on T2 weighted images.41 Definitive diagnosis is based
on typical histopathology and immunohistochemistry which
include spindle cells arranged in a storiform pattern and immunohistochemical profile staining positive for CD34, vimentin,
Bcl-2 and negative staining for actin, desmin and S-100.42
Leiomyoma
Leiomyoma is a benign smooth muscle tumour of mesenchymal
origin. Only a few cases of primary hepatic leiomyoma have
been reported.43 It can develop in healthy individuals but association with immunodeficiency and Epstein-Barr virus has been
observed.44 Histologically, the tumour may need differentiation
from gastrointestinal stromal tumours (GIST). On immunohistochemistry, leiomyomas are negative for the GIST marker
CD117.45 On imaging, it has well-defined margins rather than
an infiltrative pattern. On dynamic contrast-enhanced CT and
MRI, there is intense enhancement in the arterial phase which
persists in the portal and delayed phases without evidence of
washout.46 Low signal on T2 weighted images aids in differentiating it from a haemangioma46 (Figure 12).
Leiomyosarcoma
Primary hepatic leiomyosarcoma is rare, and most cases are
metastases from extrahepatic sites including the gastrointestinal
tract, uterus, retroperitoneum and lung.47 Serum markers such
as alpha fetoprotein tend to be normal.
Pathology shows infiltrates of spindle-shaped cells with hyperchromatic nuclei. Immunohistochemistry is positive for desmin,
vimentin, and SMA, but negative for keratin, S-100 protein, and
neuron-specific enolase. Needle biopsy will allow for definitive
diagnosis.48
CT classically demonstrates a large, marginated, heterogeneous hypodense mass with internal and peripheral enhancement (Figure 13). A cystic mass with an enhanced thickened
wall has also been reported, which may mimic an abscess or
Figure 12. Leiomyoma: axial contrast-enhanced axial CT (a)
shows a well-circumscribed oval-shaped enhancing mass
within the left hepatic lobe. Axial T2 weighted (b) image
demonstrates peripheral low signal intensity and central
hyperintensity on T2 weighted images. This demonstrated a
low signal intensity on T1 weighted image (not shown). This
mass was pathologically proven to represent a benign smooth
muscle tumour (leiomyoma).

Figure 13. Leiomyosarcoma: axial contrast-enhanced CT
showing a large heterogeneously enhancing predominantly
hypoattenuating mass (arrow) occupying the right hepatic
lobe. This was pathologically proven to represent leiomyosarcoma.

hydatid cyst.49 On MRI, it shows homogenous or heterogeneous
hypointensity on T1 weighted images, and hyperintensity on
T2 weighted images. Lack of enhancement in the arterial and
venous phases followed by marked enhancement on the delayed
phase has been reported and may be a useful finding.50
Kaposi sarcoma
Kaposi sarcoma is a low-grade malignancy associated with
human herpes virus 8 (HHV-8). It is the most common intrahepatic neoplasm in patients with AIDS, found in 34% of AIDS
patients at autopsy.51 It is also seen in solid organ transplant
recipients, although rare.52
It is typically found in the perivascular areas around the
peripheral portal branches. It consists of multiple nodules and
shows diffuse macrovacuolar steatosis, with perinodular tissue
featuring small vascular structures. By immunohistochemical
detection of endothelial cell markers such as CD31 and CD34,
Kaposi sarcoma can be differentiated from non-vascular spindle
cell neoplasms. Detection of HHV-8 LNA-1 and D2-40 is useful
to differentiate Kaposi sarcoma from other vascular tumours.53
On ultrasound, the liver appears heterogeneous with multiple
hyperechoic nodules and periportal hyperechogenecity.54 CT
shows hypoattenuating nodules which exhibit delayed enhancement (Figure 14). MRI shows nodules which are hyperintense
on T1 in-phase and hypointense on T1 out-of-phase due to the
presence of lipid.51
Mesenchymal hamartoma
Mesenchymal hamartoma (MH) is the second most common
benign liver tumour in children younger than 5 years. Less than
20 cases have been reported in adults.55 Although there are
reports of its spontaneous regression, it can potentially progress
to an aggressive malignant undifferentiated embryonal sarcoma
(UES). Therefore, surgical resection is the most favoured
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Figure 14. Kaposi’s sarcoma: axial contrast-enhanced CT (a
and c) and fused PET/CT (b and d) images demonstrate a
small hypoattenuating lesion within segment 7 of the liver
(arrows in a and b) and an enlarged right inguinal lymph node
(arrows in c and d). Both the liver lesion and inguinal lymph
node were biopsied and found to represent Kaposi’s sarcoma.

treatment option.55 A continuum between MH and UES is
considered since they share several common histopathologic,
immunohistochemical, and cytogenetic features.56
MH classically consists of variable-sized cysts. Its appearance can
vary from predominantly cystic to predominantly mesenchymal.
Its mesenchymal components show stellate cells in a loose mucopolysaccharide matrix surrounded by vessels and bile ducts.56
On ultrasound, the classic appearance is a complex cystic mass
with internal septations. A complex cystic mass with septal
and solid stromal enhancement can be seen on CT and MRI57
(Figure 15), and high signal intensity of cystic components on
T2 weighted images, with variable signal intensity on T1 weighted
images due to varying internal proteinaceous components.
Figure 15. Mesenchymal hamartoma: gray scale US (a) shows
complex cystic mass with solid component. Contrast CT
image (b) shows a complex cystic appearing right hepatic
mass, which was surgically resected and found to represent
mesenchymal hamartoma.
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Figure 16. Undifferentiated embryonal sarcoma: axial
T2 weighted image shows a large heterogeneous mass occupying the left and part of the right lobe of the liver exhibiting
increased signal intensity with several cystic areas. Axial contrast-enhanced CT (not shown) demonstrated predominant
hypoattenuation of the mass. This was pathologically proven
to be UES. UES, undifferentiated embryonal sarcoma.

Undifferentiated embryonal sarcoma
UES is a rare malignant mesenchymal tumour more common in
children, although a few cases of adult UES have been reported.58
It is the third most common primary malignant tumour of the
liver in childhood, after hepatoblastoma and hepatocellular
carcinoma.59
UES consists of sarcomatous cells associated with a myxoid
stroma. A definitive pathological diagnosis of UES is based on
immunohistochemical analysis that is positive for CD56, CD68,
vimentin and desmin. It is negative for hepatocyte paraffin 1 (aka
hep par 1) and myogenin, which differentiates UES from hepatoblastoma, HCC, and rhabdomyosarcoma (RMS), respectively.60
Discrepancy between its predominantly solid-like appearance on US and cyst-like appearance on CT has been the classical description of UES.61 This may be attributable to varying
myxoid content, which is hyperechoic on ultrasound and cystic
Figure 17. Rhabdomyosarcoma: axial contrast-enhanced CT
(a) showing a large predominantly hypoattenuating mass
occupying the left and part of the right lobe of the liver. Coronal T2 weighted images (b) demonstrate the fluid-like signal
intensity of the mass. This was pathologically proven as Rhabdomyosarcoma.
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on CT. The solid components and septations show progressive
enhancement at dynamic contrast CT/MRI (Figure 16). Gabor
et al described the presence of serpentine vessels within the
tumour on arterial phase in 10 out of 15 cases, which would be
helpful in the diagnosis of UES when a cystic lesion with internal
vessels is detected on CT.58 It is associated with a risk of spontaneous rupture which can cause hemoperitoneum and peritoneal
seeding.62 Metastases to the lungs, pleura and peritoneum have
been described.63,64
Rhabdomyosarcoma
RMS is a highly malignant tumour which may rarely arise in
the biliary tree. The mean age of presentation is 3 years and it
is rare after the first decade.65 Most patients present with jaundice and fever, mimicking hepatitis.61 It commonly arises in the
extrahepatic biliary tree, so the mass is usually adjacent to the
porta hepatis and may grow into intrahepatic biliary system,
invading the liver.66 It is histologically identical to sarcoma
botryoides, commonly arising from the bladder or vagina of
children. It therefore is at risk of being misclassified as UES.
Distinguishing the two is important because treatment differs.
Positive myogenin in RMS on immunohistochemistry helps in
distinguishing it from UES.67
Ultrasound usually demonstrates biliary dilation with an intraluminal mass, often with associated displacement of the portal vein
without intraluminal thrombus. CT shows a intraductal mass
with or without biliary dilatation.68 Hypodense and heterogeneous tumour patterns can be seen. The pattern of enhancement
also varies and may show different patterns including intense,
globular, mild or even no enhancement. On MRI, it is typically a
predominantly fluid-intensity mass which is T1 hypointense and
T2 hyperintense69(Figure 17). Although many types of masses
may cause biliary obstruction in children, only embryonal RMS
arises from the biliary tree.66

Figure 18. Metastatic GIST: axial contrast-enhanced CT shows
multiple hypoattenuating liver metastases (arrows) in a
57-year-old male patient with GIST. The lesions exhibit peripheral enhancement and central fluid attenuation. GIST, gastrointestinalstromal tumours.

Figure 19. Metastatic leiomyosarcoma: axial contrast-enhanced T1 weighted image (a) demonstrates heterogeneously enhancing mass (arrow) in segment V of the liver, which
appears hypointense relative to the surrounding parenchyma.
Axial T2 weighted image (b) demonstrates increased signal
intensity of the mass. Surgical resection and pathological
evaluation confirmed the diagnosis of metastasis from small
bowel leiomyosarcoma.

Secondary mesenchymal tumours
Mesenchymal tumours may metastasize to the liver. The liver is a
common site of metastases from leiomyosarcoma and malignant
GIST tumours.69 Metastatic GIST tumours have imaging characteristics similar to their primary tumour site. They are usually
hyperattenuating/hyperintense, enhancing masses with necrosis,
haemorrhage or cystic degeneration. Tumour vessels may be
seen within the tumour70 (Figure 18).
The most common MRI appearance of metastatic leiomyosarcoma is a well-defined homogenous mass with marked
hyperintensity on T2 weighted images, similar to a hepatic
haemangioma.71 On post-contrast imaging, it usually demonstrates peripheral rim enhancement and central necrotic areas72
(Figure 19).
Myxoid liposarcoma commonly metastasizes to the retroperitoneum, bone, and soft tissues. About one-third metastases occur
in the liver. On CT, this appears as multifocal, hypodense lesions
with minimal peripheral enhancement.73 Fat may or may not be
identified on imaging, depending on tumour differentiation73
(Figure 20).
Conclusion
Mesenchymal tumours of the liver vary widely in their imaging
appearances due to the different components that comprise
Figure 20. Metastatic liposarcoma: axial contrast-enhanced
CT shows multiple liver metastases containing fat (arrows
in a) and a large heterogeneously enhancing predominantly
mesenteric mass containing macroscopic fat (arrow in b),
consistent with metastatic liposarcoma.
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each of the various tumour types. They may be indistinguishable from other benign and malignant liver tumours, and
the diagnosis at times may only be reached after pathologic
confirmation with biopsy or resection. However, many typical

clinical and imaging findings of mesenchymal tumours have
been described. Knowledge of these distinguishing features
will aid in guiding the radiologic diagnosis and correct patient
management.
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